Having shown that SecinH3 attenuated the proliferation of gefitinib-resistant NSCLC cells we asked whether treatment with SecinH3 might render the cells responsive to gefitinib and, thus, act synergistically with this EGFR-TKI. This evidence concerns the gene EGFR and non-small cell lung carcinoma.